Navigation Links
New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence
Date:11/9/2007

6 month results from long term durability study presented at Western

Section meeting of the American Urological Association

NEWARK, Calif., Nov. 9 /PRNewswire/ -- Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that six month data from its post-market, prospective open label study to evaluate the long term durability of the Renessa(R) treatment for stress urinary incontinence (SUI) in women was presented at the Western Section meeting of the American Urological Association (AUA). A total of 137 women in the trial have been treated at 13 different sites across the United States. The patients will be followed for three years post-treatment.

Denise Elser, M.D., a urogynecologist practicing in Oak Lawn, Illinois and the principal investigator in the trial, presented the data in Scottsdale, AZ. "The non-surgical Renessa procedure offers women suffering from the isolating effects of SUI a safe, effective alternative between conservative treatments such as Kegel exercises and biofeedback, and more invasive surgical therapies," Dr. Elser said. "Women are looking for an alternative to exercise and surgery. My patients and I have been very pleased with the safety and results of this noninvasive treatment," she continued. The trial results will also be presented during a poster session at the upcoming Global Congress of Minimally Invasive Gynecology in Washington, DC.

Highlights of the six month results include:

-- 74% of women showed an improvement in their symptoms with 63% of women

reducing their episodes to less than half

-- 74% of women reported improvement in their quality of life

"This multi-center three year prospective trial is expected to confirm the outcomes seen in our previous U.S. Pivotal Trial," said Charles S. Carignan, M.D., Chief Medical Officer of Novasys Medical. "The six month results so far not only validate our earlier studies, but outcomes
'/>"/>

SOURCE Novasys Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Women everywhere know how ... not only uncomfortable, they,re often also embarrassing and have ... Feminine Health Support ( http://ph-defense.com ) is a new, ... an all-natural, homeopathic product. Odor, discharge, ... of vaginal infection. In many cases, the cause of ...
(Date:9/17/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... public offering of 4,500,000 shares of its common stock at ... share. Aratana has granted the underwriters a 30-day ... shares of its common stock. Jefferies ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. announced ... 2 clinical program of NP001 for the treatment of ... disease) are being highlighted today in an oral presentation ... Group , being held in Bloomington, Minnesota ... hoc  analysis, administration of a high dose of NP001 ...
Breaking Medicine Technology:New Product from Vireo Systems: pH-D Feminine Health Support 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
... (ASH) Annual Meeting ... Publication Number: 840, ... thromboses (blood clots),and transfusion requirements in patients with a rare ... have,been expected to have less severe disease, according to data ...
... Mich., Dec. 10 CSG/SportsCoatings and,the National Wrestling ... the most proactive and proven method of controlling,bacteria, ... Nationally renowned for its Sports Antimicrobial System (R) ... on all types of,athletic surfaces and fabrics for ...
Cached Medicine Technology:PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 2PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 3PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 4PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 5PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 6PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 7PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 8National Wrestling Coaches Association Teams Up With CSG/SportsCoatings(TM) 2
(Date:9/17/2014)... announced today that will analyze how changes in ... contribute to healthy aging. , Conducted by ... a $10 million unrestricted gift from the Amway ... identify lifestyle and environmental factors that may help ... age. WELL will be designed, conducted, and analyzed ...
(Date:9/17/2014)... In its latest blog post, Best Drug ... family close by during a stay in rehab can make ... successful, is highlighting a member of the therapeutic care team ... addicts across the country and around the world: dogs. ... blood pressure, heart rate, and stress levels in recovering addicts,” ...
(Date:9/17/2014)... Bioluminescence, nanoparticles, gene manipulation these sound like ... in fact, they are components of an exciting ... In preclinical animal models of metastatic prostate cancer, ... VCU Institute of Molecular Medicine and Johns Hopkins ... molecular imaging approach that could revolutionize doctors, ability ...
(Date:9/17/2014)... In Pretrial Order #139 (Scheduling of ... conferences would be beneficial in this [MDL].” Accordingly, the ... the end of December,” the order further provides, “the ... conferences. , “The plain import of this order ... much to be discussed as these cases progress toward ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, ... household chemicals known as phthalates might increase a child,s ... in a new study. Children had nearly an ... 5 and 11 if their mothers were exposed during ... the researchers found. The two phthalates were butylbenzyl phthalate ...
Breaking Medicine News(10 mins):Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4
... appears higher in non-Hispanic white adolescent girls and young ... in lower socioeconomic areas, according to a report posted ... issue of Archives of Dermatology , one of ... form of skin cancer and represents a substantial cause ...
... , MONDAY, March 21 (HealthDay News) -- A woman,s ... the risk of respiratory problems in her children, according to ... mother,s use of birth control pills may increase the risk ... inconclusive, said the authors of the new study. The ...
... (Mar. 21, 2011) -- A new study published by ... of California, Davis, foresees improvements in patient outcomes after ... technology. A control tower-style telemedicine hub to manage electronic ... boost the likelihood that critically injured victims will get ...
... less likely to refer short girls than short boys ... for their short stature, according to a new study ... medical conditions causing their short stature may go undiagnosed, ... treatment. Researchers from The Children,s Hospital of Philadelphia ...
... during pregnancy is common and is associated with significant ... Despite warnings from the Surgeon General to limit alcohol ... by the National Birth Defects Prevention Study(1) found that ... during their pregnancy, with one-fourth of the women surveyed ...
... Ellin Holohan HealthDay Reporter , SUNDAY, March 20 ... risk of developing diabetes and heart disease, according to a ... four other inflammatory conditions. The study, which looked at ... found higher rates of diabetes and heart illness among asthmatics ...
Cached Medicine News:Health News:Melanoma diagnosis in women associated with higher socioeconomic status 2Health News:Moms' Use of 'the Pill' Won't Raise Kids' Asthma Risk: Study 2Health News:Health information technology 'control tower' could improve earthquake response 2Health News:Medically underserved girls receive less frequent evaluation for short stature 2Health News:Medically underserved girls receive less frequent evaluation for short stature 3Health News:Adolescent offspring of women who drank alcohol during first trimester 2Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 2Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 3Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 4
18" Penrose drains...
Provides reliable suction for surgical cases with larger amounts of drainage....
Reliavac® 400cc kits with flat drain, Y-connector tubing...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Medicine Products: